Top Markets
Coin of the day
Exopharm Limited Exopharm Limited

Exopharm Limited

EX1
Rangering i aksjer #39131
Exopharm Limited is an Australian clinical-stage firm dedicated to developing... Exopharm Limited is an Australian clinical-stage firm dedicated to developing groundbreaking therapeutics utilizing extracellular vesicles (EVs). Its core technologies include an extracellular vesicle positioning system (EVPS), which facilitates the precise targeting of exosomes by attaching specific molecules to their surface, guiding them to particular tissues or cell types. Another innovation is oligonucleotide packing, designed to optimize therapeutic delivery by preferentially loading specific RNA molecules into exosomes as medicinal cargo. Additionally, Exopharm employs ligand-based exosome affinity purification for effectively isolating and refining exosomes from biological fluids such as blood and cell culture media. The company's engineered EV product portfolio features Fortrexo CoV, aimed at treating SARS-CoV-2 infections; Cognevo, developed for neurodegenerative diseases; and PlexoDox, intended for cancer treatment. Exopharm Limited also maintains a research collaboration with Showa Denko Materials Co., Ltd. The company was founded in 2013 and is headquartered in Melbourne, Australia.
Aksjekurs
$0.00700343
Sist synkronisert: 2023-10-30
Markedsverdi
$637.31K
Endring (1 dag)
0.50%
Endring (1 år)
0.00%
Land
AU
Handel Exopharm Limited (EX1)

Kategori

P/B-forhold for Exopharm Limited (EX1)
P/B-forhold per 2026 TTM: 0
Ifølge Exopharm Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Exopharm Limited fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE